459 Shares in Eli Lilly and Company (NYSE:LLY) Purchased by LifeWealth Investments LLC

LifeWealth Investments LLC purchased a new position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 459 shares of the company's stock, valued at approximately $354,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Grassi Investment Management raised its stake in Eli Lilly and Company by 0.3% in the fourth quarter. Grassi Investment Management now owns 79,512 shares of the company's stock valued at $61,383,000 after buying an additional 225 shares during the last quarter. Elevate Capital Advisors LLC acquired a new stake in Eli Lilly and Company during the fourth quarter worth about $262,000. Capital & Planning LLC grew its holdings in Eli Lilly and Company by 15.6% during the fourth quarter. Capital & Planning LLC now owns 481 shares of the company's stock worth $371,000 after acquiring an additional 65 shares during the period. Garner Asset Management Corp grew its holdings in Eli Lilly and Company by 2.3% in the fourth quarter. Garner Asset Management Corp now owns 532 shares of the company's stock valued at $411,000 after purchasing an additional 12 shares during the period. Finally, Beacon Investment Advisory Services Inc. grew its holdings in Eli Lilly and Company by 41.0% in the fourth quarter. Beacon Investment Advisory Services Inc. now owns 28,122 shares of the company's stock valued at $21,710,000 after purchasing an additional 8,172 shares during the period. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several research firms have recently weighed in on LLY. The Goldman Sachs Group upgraded Eli Lilly and Company from a "neutral" rating to a "buy" rating and decreased their target price for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their price objective for the stock from $1,150.00 to $700.00 in a research report on Monday, April 28th. Morgan Stanley restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. Wall Street Zen raised Eli Lilly and Company from a "hold" rating to a "buy" rating in a research note on Friday, February 7th. Finally, Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a research note on Friday, May 23rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $1,011.37.

Eli Lilly and Company Trading Up 0.3%

NYSE:LLY traded up $2.30 during trading hours on Thursday, hitting $721.69. The stock had a trading volume of 1,063,809 shares, compared to its average volume of 3,992,837. Eli Lilly and Company has a one year low of $677.09 and a one year high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The company has a market cap of $683.97 billion, a price-to-earnings ratio of 61.63, a P/E/G ratio of 1.40 and a beta of 0.48. The business's 50 day moving average is $782.03 and its 200-day moving average is $801.29.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to the consensus estimate of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm's revenue for the quarter was up 45.2% on a year-over-year basis. During the same period last year, the business posted $2.58 EPS. Sell-side analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be issued a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.83%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's dividend payout ratio is currently 48.82%.

Insider Activity at Eli Lilly and Company

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the business's stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the transaction, the chief accounting officer now owns 5,840 shares in the company, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by insiders.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.